Strides Arcolab gets USFDA approval for Bangalore facility

Drug firm Strides Arcolab's manufacturing facility in Bangalore has been approved by the US health regulator after a successful audit of the plant, the company said today.

"Oral Dosage Forms manufacturing site (KRS Gardens) in Bangalore was recently inspected by the US Food and Drug Administration (USFDA) as part of GMP compliance audit and the facility continues to be approved," Strides Arcolab said in a statement.

The last USFDA inspection and approval for this facility was in the year 2011, it added.

The KRS Gardens facility in Bangalore manufactures oral dosage forms such as tablets, capsules (both hard gelatine and soft gelatine) and sachets.

The manufacturing plant supports important current and future submissions for the US market, the company said.

Strides Arcolab shares were trading at Rs 505.35 apiece on the BSE in late afternoon trade, up 8.44 per cent from its previous close.


  • EPFO would do well to have better risk management of available cash

    The Employees’ Provident Fund Organisation (EPFO) is apparently revisiting its decision to invest about Rs 6,000 crore in stocks this year.


Stay informed on our latest news!


Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs


Amita Sharma

Smart cities for the smart citizens

The 21st century has been spoken of as the urban ...

Zehra Naqvi

The prejudiced childhood

Sometimes the most unusual things can remind you of the ...

Gautam Gupta

To read about online videos, click here

ONce, not so long ago, exhorbitant costs had made sure ...


William D. Green

Chairman & CEO, Accenture